The mRNA Gold Rush: Why Moderna’s “Cancer Vaccine” Hype Will Get Challenged

Mega-dose weekly mRNA part of toxic chemotherapy, however with rapid FDA approval, Intismeran poised to saddle patients with massive costs, tumor resistance, and accumulating long term safety concerns

*

After five years of being bashed on unsafe, ineffective, uncontrollable Spike protein-producing (Spikevax, mNEXSPIKE) vaccines, Moderna is solidly back home in the cancer business and their stock performance couldn’t be any better.

.

.

The mRNA Cancer Long Game: Moderna’s Pivot from Pandemic to Personalized Chemotherapy 

There’s a narrative that’s taken hold in the financial press and biotech cheerleading circles: Moderna, having saved humanity from COVID, is now developing “cancer vaccines” that will do for oncology what Operation Warp Speed did for respiratory viruses.

This is marketing, not medicine.

What Moderna is actually doing is using synthetic messenger RNA as a delivery mechanism for personalized neoantigens as a part of toxic combination chemotherapy. Calling these “vaccines” is a linguistic sleight of hand designed to borrow the halo from childhood immunization while obscuring the reality of what’s being injected into patients’ bodies week after week.

Click here to read the full article.

*

Click the share button below to email/forward this article. Follow us on Instagram and X and subscribe to our Telegram Channel. Feel free to repost Global Research articles with proper attribution.

Featured image source

Global Research is a reader-funded media. We do not accept any funding from corporations or governments. Help us stay afloat. Click the image below to make a one-time or recurring donation.